Fundraising FoxRock Springs Capital — 2024 Investments
3 investments dated 2024 · listed companies and verified rows first · show all
Korro Bio is a biotechnology company developing a new class of RNA-editing therapies guided by human genetics and disease biology.
BiotechHealthtechCambridge, US
Nessan Bermingham(Mr. Bermingham is the Executive Chair of the Issuer.)inJean-François Formela(Director)inOmmer Chohan(Mr. Chohan is the Secretary and Treasurer of the Issuer.)inRam Aiyar(Chief Executive Officer, President and Director)inTodd Chappell(Chief Operating Officer)in
Co-investorsAtlas VentureMC Healthcare VenturesNew Enterprise Associates (NEA)AlexandriaQiming Venture PartnersQiming Venture Partners USA+3 more
Arsenal Biosciences is a clinical-stage company developing programmable cell therapies to treat solid tumors.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Ken Drazan(Founder)James Ahlers(Executive Officer)Irene Pleasure(Executive Officer)Margaret Nibbi(Executive Officer)Alexander Marson(Founder)Kole Roybal(Founder)
Co-investorsARCH Venture PartnersHitachi VenturesKleiner PerkinsLuma GroupOUP (Osage University Partners)SoftBank Vision Fund+4 more
City Therapeutics develops RNAi-based medicines targeting rare, specialty, and prevalent diseases using engineered trigger molecules and precision delivery ligands.
BiotechMedical DevicesCambridge, US
Mark Keating, MD(Co-founder)Kotaro Nakanishi, PhD(Co-founder)Yukihide Tomari, PhD(Co-founder)Phillip Zamore, PhD(Co-founder)Andy Orth(Chief Executive Officer)in
Co-investorsAN Venture PartnersARCH Venture PartnersSofinnova VenturesViking GlobalAltitude Ventures Management, LlcCasdin Capital+5 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.